Xconomy Boston’s Top 20 Stories of the Third Quarter: From A123 Expansion to Zynga Acquisition

Gregory T. Huang

October 1st, 2010

The third quarter of 2010 is going out with a monsoon in New England. It seems like a good time to hole up indoors and look back at some of the top stories we’ve done at Xconomy Boston over the past three months.

These are our editors’ picks. They aren’t necessarily the ones that got the most traffic or the most attention. Rather, they are stories that highlight our unique style of on-the-scene reporting and in-depth analysis, and will stand the test of time. They range from startup profiles in health IT, security software, and drug development, to analysis pieces on leading companies’ acquisition and expansion strategies, to unique venture capital perspectives and quirky, strange-but-true facts about New England innovation leaders.

So, without further ado, here are our top 20 stories of the third quarter, in reverse chronological order (plus a bonus story, in honor of Unica founder Yuchun Lee, a former member of the MIT Blackjack Team, selling his company to IBM for $21 a share):

Genzyme Boss Henri Termeer Not Ready to Sell to Sanofi, Ride Into the Sunset, Sources Say

MeYou Health Enters Social Gaming Realm with Daily Challenge for Improving Well-Being

IBM’s Software Acquisition Strategy in Massachusetts (Plus Tips on Getting Acquired) From VP Mike Loria

Skyhook, Fighting for Its Life in Suit Against Google, Cries Foul: “Call in the Referees and Review the Tape”

Bluebird Bio, Third Rock & Genzyme’s Gene Therapy Bet, Shows Promise for Blood Disorder

Who Knew? Part 3: Xconomy Uncovers Even More Strange-But-True Facts About Boston’s Innovation Leaders

PerkinElmer Expects to Make Acquisitions After $500M Business Sale: CEO Talks Boston-Area Talent and Growth in Software, Imaging

A123 Opens Lithium Ion Battery Plant in Michigan, Wants to Create Global Hub for Electric Vehicles

Good Start Genetics Emerges from Stealth with $18M Series A Round

Reality Show Project Seeks to Capture MassChallenge Competitors in Their Entrepreneurial Element

Vertex Nails Third Big Trial With Hepatitis C Drug, In Toughest Patients to Treat … Next Page »

Single Page Currently on Page: 1 2